Bioavailability of Ubiquinol in Huntington Disease
- Conditions
- Huntington Disease
- Interventions
- Dietary Supplement: ubiquinol
- Registration Number
- NCT00980694
- Lead Sponsor
- University of Rochester
- Brief Summary
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.
Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
- Have manifest Huntington disease
- Be 18 years of age or older
- Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
- Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit
- Have a history of intolerability of sensitivity to CoQ
- Have an unstable medical or psychiatric illness
- Be pregnant or breastfeeding; women of childbearing age must use reliable contraception
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ubiquinol ubiquinol up to 600 mg per day, oral capsules for 8 weeks
- Primary Outcome Measures
Name Time Method serum coenzyme Q10 levels 8 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Rochester
🇺🇸Rochester, New York, United States